Neri Serneri Gian Gastone, Boddi Maria, Modesti Pietro Amedeo, Coppo Mirella, Cecioni Ilaria, Toscano Thomas, Papa Maria Letizia, Bandinelli Manuela, Lisi Gian Franco, Chiavarelli Mario
Clinica Medica Generale e Cardiologia, University of Florence, Viale Morgagni 85, 50134 Florence, Italy.
Circ Res. 2004 Jun 25;94(12):1630-7. doi: 10.1161/01.RES.0000130944.49657.b8. Epub 2004 May 6.
Angiotensin (Ang) II is now recognized to be a mediator of a wide variety of inflammatory processes. This study investigated renin-angiotensin system (RAS) components and a number of inflammatory mediators in left ventricular biopsies from 2-vessel disease unstable angina (UA) (n=43) and stable angina (SA) (n=15) patients undergoing coronary bypass surgery. Biopsy samples from 6 patients undergoing valve replacement for mitral stenosis served as controls. UA patients were randomly assigned to angiotensin-converting enzyme (ACE)-inhibitor (ramipril), AT1 antagonist (valsartan), or placebo and treated during the 5 days preceding coronary bypass surgery, performed from 6 to 9 days after coronary angiography. During coronary angiography coronary blood flow was measured and samples were obtained from aorta and coronary sinus for determination of Ang I and Ang II gradients. The hearts of UA patients produced Ang II in a greater amount than in SA patients (P<0.01). UA biopsy samples showed numerous DR+ cells, identified as lymphocytes, macrophages, and endothelial cells. Reverse-transcriptase polymerase chain reaction showed overexpression of AGTN, ACE, and AT1-R genes, as well as upregulation of TNF-alpha, IL-6, IFN-gamma, and iNOS genes (P<0.01), with no differences between nonischemic and potentially ischemic areas. AGTN, ACE, and cytokine genes were mainly localized on endothelial cells. Ramipril and valsartan markedly decreased the expression levels of TNF-alpha, IL-6, and iNOS, and, to a lesser extent, of IFN-gamma genes, but did not affect the number of DR+ cells, with no significant difference between the 2 treatments. These results show that locally generated Ang II amplifies the immunomediated inflammatory process of coronary microvessels occurring in unstable angina.
血管紧张素(Ang)II现在被认为是多种炎症过程的介质。本研究调查了2支血管病变不稳定型心绞痛(UA)(n = 43)和稳定型心绞痛(SA)(n = 15)患者在接受冠状动脉搭桥手术时左心室活检中的肾素-血管紧张素系统(RAS)组分和多种炎症介质。6例因二尖瓣狭窄接受瓣膜置换术的患者的活检样本作为对照。UA患者被随机分配至血管紧张素转换酶(ACE)抑制剂(雷米普利)、AT1拮抗剂(缬沙坦)或安慰剂组,并在冠状动脉造影后6至9天进行冠状动脉搭桥手术前的5天内接受治疗。在冠状动脉造影期间测量冠状动脉血流,并从主动脉和冠状窦获取样本以测定Ang I和Ang II梯度。UA患者心脏产生的Ang II量比SA患者更多(P<0.01)。UA活检样本显示大量DR+细胞,鉴定为淋巴细胞、巨噬细胞和内皮细胞。逆转录酶聚合酶链反应显示AGTN、ACE和AT1-R基因过表达,以及TNF-α、IL-6、IFN-γ和iNOS基因上调(P<0.01),非缺血区和潜在缺血区之间无差异。AGTN、ACE和细胞因子基因主要定位于内皮细胞。雷米普利和缬沙坦显著降低TNF-α、IL-6和iNOS的表达水平,在较小程度上降低IFN-γ基因的表达水平,但不影响DR+细胞数量,两种治疗之间无显著差异。这些结果表明,局部产生的Ang II会放大不稳定型心绞痛中发生的冠状动脉微血管免疫介导的炎症过程。